Vor Biopharma reports third quarter loss and reduced R&D expenses
I'm PortAI, I can summarize articles.
Vor Biopharma Inc. reported a net loss of $812.7 million for Q3 2025, a significant increase from $27.6 million in Q3 2024. Operating expenses slightly decreased to $28.1 million, with R&D expenses down to $14.1 million due to reduced stock-based compensation and headcount. Cash reserves were $170.5 million, with funding projected into Q2 2027. The company expanded its leadership and highlighted late-stage data for telitacicept.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments